VLA15 not checked

Pfizer · PF-07307405

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
2 active
8 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will receive IM injection of 6-valent OspA-based Lyme disease vaccine”In the company’s words, NCT07226882 on ClinicalTrials.gov
Tested for
Lyme Disease, Lyme Borreliosis
Main trialPhase 3
“The purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine. This study is seeking participants who: * are generally healthy and 7 years of age and older, * have already been vaccinated with 4 doses of VLA15 (from the VALOR study), and have blood sample taken post dose 4. * are not currently taking, or haven't recently taken, medicines like chemotherapy, blood products, or blood thinners. * are not pregnant or breastfeeding and do not plan to become pregnant…”In the company’s words, NCT07500506 on ClinicalTrials.gov
Other names
PF-07307405

Other drugs for Lyme Disease

All 4 drugs for Lyme Disease

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 4 Dec 2026 A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine
Phase 3Active, not recruiting 27 Jan 2028 A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults
Phase 3Completed 21 Jul 2025 Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children
Phase 3Completed 7 Jan 2026 An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
Phase 2Completed 18 Dec 2019 Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.
Phase 2Completed 7 Apr 2020 Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis
Phase 2Completed 25 Mar 2022 Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population
Phase 1Completed 28 Sep 2017 Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow VLA15

Following is part of Solo: you see every change to VLA15 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in